MX370676B - Derivado de 1,3-benzodioxol. - Google Patents
Derivado de 1,3-benzodioxol.Info
- Publication number
- MX370676B MX370676B MX2016011825A MX2016011825A MX370676B MX 370676 B MX370676 B MX 370676B MX 2016011825 A MX2016011825 A MX 2016011825A MX 2016011825 A MX2016011825 A MX 2016011825A MX 370676 B MX370676 B MX 370676B
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- benzodioxole
- benzodioxole derivative
- Prior art date
Links
- 150000005529 1,3-benzodioxoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 abstract 2
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FTNJQNQLEGKTGD-ZFJHNFROSA-N 1,3-benzodioxole Chemical group C1O[13C]=2[13CH]=[13CH][13CH]=[13CH][13C]=2O1 FTNJQNQLEGKTGD-ZFJHNFROSA-N 0.000 abstract 1
- 101001028782 Homo sapiens Histone-lysine N-methyltransferase EZH1 Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un compuesto que tiene una estructura química particular y que tiene un excepcional efecto inhibidor sobre la actividad de EZH1 y/o EZH2 o una sal farmacológicamente aceptable del mismo. Un compuesto que tiene una estructura de 1,3-benzodioxol representado por la fórmula general (I) o una sal farmacológicamente aceptable del mismo, o una composición farmacéutica que comprende el compuesto (R1, R2, R3, R4, R5, R6 y V en la fórmula (I) son cada uno como se definen en la presente memoria descriptiva). (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014053235 | 2014-03-17 | ||
| PCT/JP2015/057652 WO2015141616A1 (ja) | 2014-03-17 | 2015-03-16 | １，３－ベンゾジオキソール誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016011825A MX2016011825A (es) | 2016-12-16 |
| MX370676B true MX370676B (es) | 2019-12-19 |
Family
ID=54144584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011825A MX370676B (es) | 2014-03-17 | 2015-03-16 | Derivado de 1,3-benzodioxol. |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10017500B2 (es) |
| EP (1) | EP3121175B1 (es) |
| JP (1) | JP5806438B1 (es) |
| KR (1) | KR102302830B1 (es) |
| CN (1) | CN106132954B (es) |
| AU (1) | AU2015232543B2 (es) |
| BR (1) | BR112016020621B1 (es) |
| CA (1) | CA2942883C (es) |
| CY (1) | CY1122821T1 (es) |
| DK (1) | DK3121175T3 (es) |
| ES (1) | ES2774900T3 (es) |
| HR (1) | HRP20200354T1 (es) |
| HU (1) | HUE049417T2 (es) |
| IL (1) | IL247836B (es) |
| LT (1) | LT3121175T (es) |
| MX (1) | MX370676B (es) |
| MY (1) | MY192603A (es) |
| NZ (1) | NZ723312A (es) |
| PH (1) | PH12016501813B1 (es) |
| PL (1) | PL3121175T3 (es) |
| PT (1) | PT3121175T (es) |
| RS (1) | RS60022B1 (es) |
| RU (1) | RU2679131C2 (es) |
| SG (1) | SG11201607006TA (es) |
| SI (1) | SI3121175T1 (es) |
| TW (1) | TWI648275B (es) |
| WO (1) | WO2015141616A1 (es) |
| ZA (1) | ZA201605622B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2774900T3 (es) | 2014-03-17 | 2020-07-23 | Daiichi Sankyo Co Ltd | Derivados de 1,3-benzodioxol como inhibidores de EZH1 y/o EZH2 |
| WO2017018499A1 (ja) * | 2015-07-30 | 2017-02-02 | 第一三共株式会社 | 成人ｔ細胞白血病リンパ腫の治療及び／又は予防剤 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| CN106588914B (zh) * | 2015-10-16 | 2018-11-02 | 陈剑 | 具有取代吡啶并咪唑类衍生物，其制备及其在医药上的应用 |
| RS59763B1 (sr) | 2015-11-19 | 2020-02-28 | Jiangsu hengrui medicine co ltd | Derivati benzofurana, postupci njihove pripreme i njihova upotreba u medicini |
| WO2017199227A1 (en) | 2016-05-20 | 2017-11-23 | S & I Ophthalmic, Llc. | Process for preparation of 3,4-dihydroxy-2-methyl benzoic acid alkylester |
| KR101770302B1 (ko) * | 2016-06-28 | 2017-08-22 | 주식회사 녹십자 | 다이페닐메탄 유도체의 제조방법 |
| CN106727556B (zh) * | 2016-11-30 | 2017-10-20 | 鑫喆喆 | 一种治疗脑损伤的药物组合物 |
| US11046710B2 (en) | 2016-12-23 | 2021-06-29 | Daiichi Sankyo Company, Limited | Sulfonamide compounds |
| AU2018210099A1 (en) | 2017-01-19 | 2019-08-15 | Daiichi Sankyo Company, Limited | Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| US11311513B2 (en) | 2017-04-26 | 2022-04-26 | University Of Cincinnati | Methods, agents, and compositions for the treatment of acute myeloid leukemia |
| MX2019012967A (es) | 2017-05-18 | 2020-01-20 | Jiangsu Hengrui Medicine Co | Cristal de base libre de derivados benzofurano y metodo de preparacion. |
| CA3075892C (en) | 2017-09-14 | 2024-01-23 | Daiichi Sankyo Company, Limited | Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases |
| JP7295105B6 (ja) | 2017-11-10 | 2023-07-24 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | ベンゾフラン誘導体の製造方法 |
| CA3089639C (en) | 2018-01-31 | 2024-06-18 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidinyl compounds as prc2 inhibitors |
| EA202092490A1 (ru) | 2018-04-18 | 2020-12-23 | Констеллейшен Фармасьютикалс, Инк. | Модуляторы метилмодифицирующих ферментов, композиции и их применения |
| US11919912B2 (en) | 2018-05-21 | 2024-03-05 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP7411256B2 (ja) * | 2018-07-27 | 2024-01-11 | エボポイント、バイオサイエンシズ、カンパニー、リミテッド | 多置換ベンゼン環化合物、製造方法及びその用途 |
| JP7479292B2 (ja) | 2018-11-29 | 2024-05-08 | 第一三共株式会社 | 組み合わせ医薬として用いられるｅｚｈ１／２二重阻害剤を含有する医薬組成物 |
| KR20200101219A (ko) * | 2019-02-19 | 2020-08-27 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
| BR112022001154A2 (pt) * | 2019-07-24 | 2022-06-07 | Constellation Pharmaceuticals Inc | Terapias de inibição de ezh2 para o tratamento de cânceres |
| KR20220041129A (ko) * | 2019-07-24 | 2022-03-31 | 콘스텔레이션 파마슈티칼스, 인크. | 7-클로로-2-(4-(3-메톡시아제티딘-1-일)사이클로헥실)-2,4-디메틸-n-((6-메틸-4-(메틸티오)-2-옥소-1,2-디하이드로피리딘-3-일)메틸)벤조[d][1,3]디옥솔-5-카르복사미드의 결정질 형태 |
| AU2020325143A1 (en) | 2019-08-08 | 2022-02-24 | Daiichi Sankyo Company, Limited | Therapeutic agent for cancer having resistance to anti-CCR4 antibody |
| WO2021035194A1 (en) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| CN115175905A (zh) * | 2020-03-13 | 2022-10-11 | 四川海思科制药有限公司 | Zeste增强子同源物2抑制剂及其用途 |
| JPWO2022009911A1 (es) | 2020-07-08 | 2022-01-13 | ||
| MX2023001603A (es) | 2020-08-13 | 2023-03-07 | Hanmi Pharmaceutical Co Ltd | Derivados de dioxoloisoquinolinona novedosos y uso de los mismos. |
| KR102386403B1 (ko) * | 2020-08-13 | 2022-04-15 | 한미약품 주식회사 | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 |
| CN118234494A (zh) | 2021-11-10 | 2024-06-21 | 第一三共株式会社 | 具有优异溶出性质的药物组合物 |
| CN114149297A (zh) * | 2021-12-07 | 2022-03-08 | 北京中医药大学 | 一种微波辅助的选择性芳基甲醛的绿色合成方法 |
| CN116496263A (zh) * | 2022-01-27 | 2023-07-28 | 江苏天士力帝益药业有限公司 | Ezh1/2抑制剂及其制备和抗肿瘤治疗中的应用 |
| TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
| WO2023217018A1 (zh) * | 2022-05-07 | 2023-11-16 | 贝达药业股份有限公司 | Ezh2抑制剂及其在医药上的应用 |
| WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| CN115974856B (zh) * | 2022-12-28 | 2023-08-11 | 北京康立生医药技术开发有限公司 | 一种治疗成人t细胞白血病淋巴瘤药物伐美妥司他的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| US20090012031A1 (en) * | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
| WO2013067302A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| CN104039956A (zh) * | 2011-11-04 | 2014-09-10 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 治疗方法 |
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013173441A2 (en) * | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| WO2014055634A1 (en) * | 2012-10-02 | 2014-04-10 | Yale University | Identification of small molecule inhibitors of jumonji at-rich interactive domain 1a (jarid1a) and 1b (jarid1b) histone demethylase |
| EP2908843B1 (en) | 2012-11-19 | 2019-09-04 | Agency For Science, Technology And Research | Treating cancer |
| ES2774900T3 (es) | 2014-03-17 | 2020-07-23 | Daiichi Sankyo Co Ltd | Derivados de 1,3-benzodioxol como inhibidores de EZH1 y/o EZH2 |
-
2015
- 2015-03-16 ES ES15765525T patent/ES2774900T3/es active Active
- 2015-03-16 JP JP2015534847A patent/JP5806438B1/ja active Active
- 2015-03-16 BR BR112016020621-5A patent/BR112016020621B1/pt active IP Right Grant
- 2015-03-16 RU RU2016140420A patent/RU2679131C2/ru active
- 2015-03-16 EP EP15765525.9A patent/EP3121175B1/en active Active
- 2015-03-16 CN CN201580014878.3A patent/CN106132954B/zh active Active
- 2015-03-16 PT PT157655259T patent/PT3121175T/pt unknown
- 2015-03-16 HU HUE15765525A patent/HUE049417T2/hu unknown
- 2015-03-16 DK DK15765525.9T patent/DK3121175T3/da active
- 2015-03-16 MX MX2016011825A patent/MX370676B/es active IP Right Grant
- 2015-03-16 LT LTEP15765525.9T patent/LT3121175T/lt unknown
- 2015-03-16 MY MYPI2016001687A patent/MY192603A/en unknown
- 2015-03-16 CA CA2942883A patent/CA2942883C/en active Active
- 2015-03-16 US US15/123,523 patent/US10017500B2/en active Active
- 2015-03-16 AU AU2015232543A patent/AU2015232543B2/en active Active
- 2015-03-16 WO PCT/JP2015/057652 patent/WO2015141616A1/ja active Application Filing
- 2015-03-16 TW TW104108302A patent/TWI648275B/zh active
- 2015-03-16 PL PL15765525T patent/PL3121175T3/pl unknown
- 2015-03-16 SI SI201531090T patent/SI3121175T1/sl unknown
- 2015-03-16 KR KR1020167024813A patent/KR102302830B1/ko active IP Right Grant
- 2015-03-16 RS RS20200240A patent/RS60022B1/sr unknown
- 2015-03-16 NZ NZ72331215A patent/NZ723312A/en unknown
- 2015-03-16 SG SG11201607006TA patent/SG11201607006TA/en unknown
-
2016
- 2016-08-15 ZA ZA2016/05622A patent/ZA201605622B/en unknown
- 2016-09-15 IL IL247836A patent/IL247836B/en active IP Right Grant
- 2016-09-16 PH PH12016501813A patent/PH12016501813B1/en unknown
-
2018
- 2018-06-07 US US16/002,297 patent/US10954219B2/en active Active
-
2020
- 2020-03-03 HR HRP20200354TT patent/HRP20200354T1/hr unknown
- 2020-03-04 CY CY20201100194T patent/CY1122821T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501813A1 (en) | 1,3-benzodioxole derivative | |
| PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| WO2016011390A8 (en) | Irak4 inhibiting agents | |
| MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
| PH12017500416A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2018009459A (es) | Derivado de sulfonamida y composicion farmaceutica que contiene el mismo. | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| MX2018003554A (es) | Benzamidas sustituidas con isoxazolina y analogos como insecticidas. | |
| MX2016009794A (es) | Derivado de sulfonamida heterociclico y medicina que comprende el mismo. | |
| MY162886A (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
| GEP20186910B (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
| PH12018500378B1 (en) | Novel annelated phenoxyacetamides | |
| NZ731607A (en) | Dihydropyrimidin-2- one compounds and medical use thereof | |
| MX2018001517A (es) | Derivados sustituidos de guanidina. | |
| WO2018039077A8 (en) | Therapeutic compounds | |
| PH12020550403A1 (en) | Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof | |
| PH12016502568A1 (en) | Novel heterocyclic compound | |
| MX2016013439A (es) | Formas solidas de un compuesto farmaceuticamente activo. | |
| MX2016013684A (es) | Composicion farmaceutica que contiene derivado de hidantoina. | |
| MX2019007786A (es) | Compuestos sustituidos de guanidina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |